A multinational Delphi consensus to end the COVID-19 public health threat

Nature, Journal Year: 2022, Volume and Issue: 611(7935), P. 332 - 345

Published: Nov. 3, 2022

Abstract Despite notable scientific and medical advances, broader political, socioeconomic behavioural factors continue to undercut the response COVID-19 pandemic 1,2 . Here we convened, as part of this Delphi study, a diverse, multidisciplinary panel 386 academic, health, non-governmental organization, government other experts in from 112 countries territories recommend specific actions end persistent global threat public health. The developed set 41 consensus statements 57 recommendations governments, health systems, industry key stakeholders across six domains: communication; systems; vaccination; prevention; treatment care; inequities. In wake nearly three years fragmented national responses, it is instructive note that highest-ranked call for adoption whole-of-society whole-of-government approaches 1 , while maintaining proven prevention measures using vaccines-plus approach 2 employs range financial support complement vaccination. Other with at least 99% combined agreement advise governments improve communication, rebuild trust engage communities 3 management responses. findings which have been further endorsed by 184 organizations globally, include points unanimous agreement, well >5% disagreement, provide social policy address inadequacies help bring an end.

Language: Английский

---

Wastewater surveillance of pathogens can inform public health responses

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(10), P. 1992 - 1995

Published: Sept. 8, 2022

Language: Английский

---

Long COVID and Significant Activity Limitation Among Adults, by Age — United States, June 1–13, 2022, to June 7–19, 2023

MMWR Morbidity and Mortality Weekly Report, Journal Year: 2023, Volume and Issue: 72(32), P. 866 - 870

Published: Aug. 10, 2023

Long COVID is a condition encompassing wide range of health problems that emerge, persist, or return following COVID-19. CDC analyzed national repeat cross-sectional Household Pulse Survey data to estimate the prevalence long and significant related activity limitation among U.S. adults aged ≥18 years by age group. Data from surveys completed between June 1-13, 2022, 7-19, 2023, indicated decreased 7.5% (95% CI = 7.1-7.9) 6.0% 5.7-6.3) overall adult population, irrespective history previous COVID-19, 18.9% 17.9-19.8) 11.0% 10.4-11.6) reporting Among both groups, through January 4-16, before stabilizing. When stratified age, only <60 experienced rates decline (p<0.01). those 30-79 fall winter then stabilized. During 26.4% 24.0-28.9) with reported limitation, which did not change over time. These findings help guide ongoing COVID-19 prevention efforts planning for symptom management future care service needs.

Language: Английский

---

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

MMWR Morbidity and Mortality Weekly Report, Journal Year: 2022, Volume and Issue: 71(29), P. 931 - 939

Published: July 15, 2022

The Omicron variant (B.1.1.529) of SARS-CoV-2, the virus that causes COVID-19, was first identified in United States November 2021, with BA.1 sublineage (including BA.1.1) causing largest surge COVID-19 cases to date. sublineages BA.2 and BA.2.12.1 emerged later by late April 2022, accounted for most cases.* Estimates vaccine effectiveness (VE) can be reduced newly emerging variants or evade vaccine-induced immunity (1), protection from previous SARS-CoV-2 infection unvaccinated persons (2), increasing time since vaccination (3). Real-world data comparing VE during periods when BA.2/BA.2.12.1 predominated (BA.1 period period, respectively) are limited. VISION network† examined 214,487 emergency department/urgent care (ED/UC) visits 58,782 hospitalizations a COVID-19-like illness§ diagnosis among 10 states December 18, 2021-June 10, evaluate 2, 3, 4 doses mRNA vaccines (BNT162b2 [Pfizer-BioNTech] mRNA-1273 [Moderna]) compared no adults without immunocompromising conditions. against COVID-19-associated hospitalization 7-119 days ≥120 after receipt dose 3 92% (95% CI = 91%-93%) 85% 81%-89%), respectively, 69% 58%-76%) 52% 44%-59%), period. Patterns were similar ED/UC encounters. Among aged ≥50 years, 55% 46%-62%) ≥7 (median 27 days) fourth 80% 71%-85%) predominance. Immunocompetent should receive recommended booster prevent moderate severe including all eligible second years at least months an initial dose. Booster obtained immediately become eligible.¶.

Language: Английский

---

Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status — United States, April 2021–September 2022

MMWR Morbidity and Mortality Weekly Report, Journal Year: 2023, Volume and Issue: 72(22), P. 601 - 605

Published: June 1, 2023

Changes in testing behaviors and reporting requirements have hampered the ability to estimate U.S. SARS-CoV-2 incidence (1). Hybrid immunity (immunity derived from both previous infection vaccination) has been reported provide better protection than that or vaccination alone (2). To of prevalence infection- vaccination-induced antibodies (or both), data a nationwide, longitudinal cohort blood donors were analyzed. During second quarter 2021 (April-June), an estimated 68.4% persons aged ≥16 years had antibodies, including 47.5% alone, 12.0% 8.9% both. By third 2022 (July-September), 96.4% vaccination, 22.6% 26.1% alone; 47.7% hybrid immunity. Prevalence was lowest among ≥65 (36.9%), group with highest risk for severe disease if infected, those 16-29 (59.6%). Low infection-induced older adults reflects success public health prevention efforts while also highlighting importance staying up date recommended COVID-19 at least 1 bivalent dose.*,†.

Language: Английский

---

Seasonal trends in COVID-19 cases, hospitalizations, and mortality in the United States and Europe

Scientific Reports, Journal Year: 2023, Volume and Issue: 13(1)

Published: March 8, 2023

Abstract Determining whether SARS-CoV-2 exhibits seasonality like other respiratory viruses is critical for public health planning. We evaluated COVID-19 rates follow a seasonal pattern using time series models. used decomposition to extract the annual component of case, hospitalization, and mortality from March 2020 through December 2022 United States Europe. Models were adjusted country-specific stringency index account confounding by various interventions. Despite year-round disease activity, we identified spikes in approximately November April all outcomes countries. Our results support employing preventative measures against SARS-CoV-2, such as administering booster vaccines similar timeframe those place influenza. Whether certain high-risk individuals may need more than one vaccine dose each year will depend on factors durability severe illness levels activity.

Language: Английский

---

SARS-CoV-2 in immunocompromised individuals

Immunity, Journal Year: 2022, Volume and Issue: 55(10), P. 1779 - 1798

Published: Sept. 13, 2022

Language: Английский

---

Wastewater surveillance of SARS-CoV-2 and influenza in preK-12 schools shows school, community, and citywide infections

Water Research, Journal Year: 2023, Volume and Issue: 231, P. 119648 - 119648

Published: Jan. 20, 2023

Language: Английский

---

More than a Tripledemic: Influenza A Virus, Respiratory Syncytial Virus, SARS-CoV-2, and Human Metapneumovirus in Wastewater during Winter 2022–2023

Environmental Science & Technology Letters, Journal Year: 2023, Volume and Issue: 10(8), P. 622 - 627

Published: July 20, 2023

Wastewater monitoring can provide insights into respiratory disease occurrence in communities that contribute to the wastewater system. Using daily measurements of RNA influenza A (IAV), syncytial virus (RSV), and human metapneumovirus (HMPV), as well SARS-CoV-2 solids from eight publicly owned treatment works Greater San Francisco Bay Area California between July 2022 early 2023, we identify a "tripledemic" when concentrations IAV, RSV, peaked at approximately same time. HMPV was also widely circulating. We designed novel hydrolysis probe RT-PCR assays for different IAV subtype markers discern dominant circulating H3N2. show data be used onset offset events. This information insight epidemiology timely, localized inform hospital staffing clinical decision making respond viruses. Whereas RSV events were mostly regionally coherent, displayed patterns.

Language: Английский

---

Delayed medical care and underlying health in the United States during the COVID-19 pandemic: A cross-sectional study

Preventive Medicine Reports, Journal Year: 2022, Volume and Issue: 28, P. 101882 - 101882

Published: July 5, 2022

This study assesses the association between underlying health conditions and delaying medical care during COVID-19 pandemic. An online cross-sectional survey administered by OutbreaksNearMe.org on Momentive.ai collected self-reported data from April 27 to June 2, 2020 May 10 13, 2021. We used weighted multivariable logistic regressions assess status, adjusting for demographics. Of 312,661 total responses (99.6% completion rate), 17.1% reported delayed care. Compared good health, those with poor were more likely delay (AOR = 2.62, 95% CI [2.47, 2.78]). Individuals any condition 1.62, [1.58, 1.65]) each of Differences in observed across region, year, Our finding is that at higher risk severe 2021, which could exacerbate existing disparities.

Language: Английский

---